Inactive Instrument

ISRAEL CAP C

Equities

IL.P

CA46503P1099

Israel Capital Canada Corp. Reports Earnings Results for the First Quarter Ended January 31, 2022

March 29, 2022

Israel Capital Canada Corp. reported earnings results for the first quarter ended January 31, 2022. For the first quarter, the company reported net loss was CAD 0.007268 million compared to CAD 0.026981 million a year ago.

Latest news about ISRAEL CAP C

Israel Capital Canada Corp. Reports Earnings Results for the First Quarter Ended January 31, 2022	22-03-29	CI
Israel Capital Canada Corp. Reports Earnings Results for the Full Year Ended October 31, 2021	22-02-28	CI
FREmedica Technologies Inc. completed the acquisition of Israel Capital Canada Corp. (TSXV:IL.P) in a reverse merger transaction.	22-02-01	CI
Israel Capital Canada Corp. announced that it has received CAD 2.524374 million in funding	22-01-19	CI
Israel Capital Canada Corp. Reports Earnings Results for the Third Quarter Ended July 31, 2021	21-09-29	CI
FREmedica Technologies Inc. agreed to acquire Israel Capital Canada Corp. (TSXV:IL.P) in a reverse merger transaction.	21-04-11	CI
Israel Capital Canada Corp. Reports Earnings Results for the First Quarter Ended January 31, 2021	21-03-30	CI
Israel Capital Canada Corp. announced a financing transaction	20-10-12	CI
Israel Capital Canada Corp. announced that it has received CAD 0.177201 million in funding	20-06-18	CI
Israel Capital Canada Corp. announced that it expects to receive CAD 0.15 million in funding	20-05-11	CI
Israel Capital Canada Corp. has completed an IPO in the amount of CAD 0.2 million.	20-05-08	CI
Israel Capital Canada Corp. has filed an IPO in the amount of CAD 0.2 million.	20-03-06	CI

Chart ISRAEL CAP C

Duration

Period

More charts

Company Profile

Frequency Exchange Corp., formerly Israel Capital Canada Corp, is a Canada-based company. The Company focuses on the development and commercialization of a frequency emitter that delivers a special package of frequencies designed for the health and wellness market, specifically to target Lyme disease within North America. The Company offers Wave 1, which is the third-generation frequency emitter. It is the second wearable technology designed specifically to deliver frequencies to help clients with chronic Lyme disease. The technology combined with the frequencies is based on development and experimentation in bio-energetic technology.

Sector

More about the company